ASLAN Pharmaceuticals - ADR Financials

$0.60

$-- (--%)

As on 16-Aug-2024 09:30EDT

Market cap

$2 Mln

Revenue (TTM)

$12 Mln

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	12.00	12.00	12.00	--	--	3.00
Cost of Revenue	--	0.35	0.33	0.28	0.30	0.41
Gross Profit	12.00	11.65	-0.33	-0.28	-0.30	2.59
Operating Expenses	46.85	55.39	47.88	33.85	16.48	48.17
Operating Profit (EBIT)	-34.85	-43.74	-47.88	-33.85	-16.48	-45.58
Other Income	--	--	--	--	--	--
Profit before Tax	-34.90	-44.08	-51.28	-31.59	-16.97	-46.66
Provision for Tax	0.13	0.13	0.10	3.12	0.93	0.41
Profit after Tax (Net Income)	-35.03	-44.22	-51.38	-34.71	-17.91	-47.07
Minority Interest	--	--	--	0.27	0.30	32.17
Consolidated Profit	-1.89	--	-51.38	-31.32	-16.20	-1,450.52

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	-17.96	-13.29	8.37	57.30	-10.45	-1.68
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	19.35	24.80	29.66	30.86	15.58	18.57
Current Liabilities	19.60	13.11	23.16	6.36	10.66	5.38
Total Liabilities	40.59	24.63	61.19	94.52	16.08	23.35

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	0.41	0.50	0.31	0.74	0.58	1.08
Current Assets	20.58	24.13	60.88	93.78	15.50	22.27
Total Assets	40.59	24.63	61.19	94.52	16.08	23.35
Total Debt*	26.67	26.83	37.62	31.06	19.26	543.08
Net Current Assets	0.97	11.02	37.71	87.42	4.84	16.89

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-46.36	-38.41	-34.00	-15.05	-25.80
Cash Flow from Investing Activities	--	-0.01	0.41	-0.03	0.00	0.01
Cash from Financing Activities	--	10.72	4.72	109.87	7.17	19.09
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	-30.29	-0.10	-92.08	-62.34	-43.51	-6.97
Cash EPS ($)	--	-0.10	-91.49	-61.83	-42.79	-6.91
Adjusted Book Value ($)	--	--	14.99	102.92	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.11	-68.83	-61.06	-36.58	-3.82
Free Cash Flow per Share ($)	--	-0.11	-68.88	-61.14	-36.59	-3.82

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-148.58	-76.49	-71.45	-6.51	-9.42
ROE (%)	--	1,796.92	-156.49	-148.17	295.23	-325.26
ROA (%)	-56.43	-103.06	-66.00	-62.77	-90.82	-123.48
EBIT Margin (%)	-184.02	-364.46	-399.49	--	--	-1,540.01
Net Margin (%)	-291.89	-368.50	-428.19	--	--	-1,568.85
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	--	--	--	--	-1.00	--
EBIT Growth (%)	59.18	8.77	-48.33	-101.72	65.32	-10.85
Net Profit Growth (%)	38.99	13.94	-48.04	-93.84	61.95	-11.57
EPS Growth (%)	69.97	1.00	-0.48	-0.43	-5.24	-3.96
Book Value Growth (%)	-244.26	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	--	-5.19	0.00	-0.02	-0.04	-0.29
Price / Book Value	2.14	-17.28	0.02	0.01	-0.07	-8.17
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.35	-5.42	0.40	1.83	-0.35	-11.68
Close Price ($)	4.92	4.18	14.40	44.80	73.20	81.20
High Price ($)	37.52	37.52	49.20	270.00	114.00	327.20
Low Price ($)	3.14	3.14	13.62	42.80	33.20	14.00
Market Cap ($ Cr)	1.70	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	-1.08	-2.02	4.50	0.54	-1.84	-323.77
Short term debt to equity ratio	-0.41	-0.15	0.95	0.00	-0.36	-0.16
Current Ratio	1.05	1.84	2.63	14.75	1.45	4.14
Quick Ratio	1.05	--	--	--	--	4.14
Interest Coverage	-7.91	-10.11	-13.04	-17.37	-12.84	-51.24

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	1.43	1.43	--	--	--	--
Asset Turnover	0.19	0.28	0.15	--	--	0.08
Receivable days	--	5.22	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	10,849.14	8,753.44	3,517.82	2,570.73	3,223.09
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.